Moreover, the East–West Route should pave the way for the preparation of more complex APN analogues and an in-depth exploration of the structure–activity relationship to develop new lead compounds of higher potency as antagonists of APC/C activation by Cdc20 in breast cancer cells and other cancer types of different tissue origins. Here, CDC20 is linked to breast cancer.